BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27404943)

  • 1. Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice.
    Mousavi Niri N; Memarnejadian A; Pilehvar-Soltanahmadi Y; Agha Sadeghi M; Mahdavi M; Kheshtchin N; Arab S; Namdar A; Jadidi F; Zarghami N; Hajati J
    J Immunother; 2016 Sep; 39(7):269-75. PubMed ID: 27404943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducing Humoral Immune Responses Against Regulatory T Cells by Foxp3-Fc(IgG) Fusion Protein.
    Niri NM; Hadjati J; Sadat M; Memarnejadian A; Aghasadeghi M; Akbarzadeh A; Zarghami N
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):381-5. PubMed ID: 26683176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.
    Mousavi-Niri N; Naseroleslami M; Hadjati J
    Hum Vaccin Immunother; 2019; 15(3):620-624. PubMed ID: 30633616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
    Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
    Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.
    Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY
    Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
    Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
    Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination.
    Stifter K; Schuster C; Schlosser M; Boehm BO; Schirmbeck R
    Sci Rep; 2016 Jul; 6():29419. PubMed ID: 27406624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
    de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
    Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
    Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
    Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
    Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
    Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice.
    Suffner J; Hochweller K; Kühnle MC; Li X; Kroczek RA; Garbi N; Hämmerling GJ
    J Immunol; 2010 Feb; 184(4):1810-20. PubMed ID: 20083650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
    Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
    J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.